Rory Shallis

Dr. Rory Shallis

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 July 2018 in European Journal of Haematology
Verified
Journal Article
Open access
PDF file
RSRory Shallis
Rory Shallis
RARami Ahmad
Rami Ahmad
Amer M. ZeidanAmer M. Zeidan
Amer M. Zeidan
Aplastic anemia (AA) is rare disorder of bone marrow failure which if severe and not appropriately treated is highly fatal. AA is characterized by morphologic marrow features, namely hypocellularity, and resultant peripheral cytopenias. The molecular pathogenesis of AA is not fully understood, and a uniform process may not be the culprit across all cases. An antigen‐driven and likely autoimmune dysregulated T‐cell homeostasis is implicated in the hematopoietic stem cell injury which ultimately founds the pathologic features of the disease. Defective telomerase function and repair may also play a role in some cases as evidenced by recurring mutations in related telomerase complex genes such asTERTandTERC. In addition, recurring mutations inBCOR/BCORL, PIGA, DNMT3A,andASXL1as well as cytogenetic abnormalities, namely monosomy 7, trisomy 8, and uniparental disomy of the 6p arm seem to be intimately related to AA pathogenesis. The increased incidence of late clonal disease has also provided clues to accurately describe plausible predispositions to the development of AA. The emergence of newer genomic sequencing and other techniques is incrementally improving the understanding of the pathogenic mechanisms of AA, the detection of the disease, and ultimately offers the potential to improve patient outcomes. In this comprehensive review, we discuss the current understanding of the immunobiology, molecular pathogenesis, and future directions of such for AA.

4 March 2020 in Leukemia
Verified
Journal Article
Closed access
PDF file
MSMaximilian Stahl
Maximilian Stahl
RSRory Shallis
Rory Shallis
WWWei Wei
Wei Wei
PMPau Montesinos
Pau Montesinos
ELEtienne Lengline
Etienne Lengline
Amer M. ZeidanAmer M. Zeidan
Amer M. Zeidan

20 May 2020 in Blood Advances
Verified
Journal Article
Open access
PDF file
Amer M. ZeidanAmer M. Zeidan
Amer M. Zeidan
RWRong Wang
Rong Wang
XWXiaoyi Wang
Xiaoyi Wang
RSRory Shallis
Rory Shallis
NPNikolai A. Podoltsev
Nikolai A. Podoltsev
XMXiaomei Ma
Xiaomei Ma
The hypomethylating agents (HMAs) azacitidine and decitabine have been the de facto standard of care for patients with acute myeloid leukemia (AML) who are unfit for intensive therapy. Using the Surveillance, Epidemiology, and End Results-Medicare linked database, we identified 2263 older adults (age ≥66 years) diagnosed with AML during 2005-2015 who received a first-line HMA; 1154 (51%) received azacitidine, and 1109 (49%) received decitabine. Median survival from diagnosis was 7.1 and 8.2 months (P < .01) for azacitidine- and decitabine-treated patients, respectively. Mortality risk was higher with azacitidine vs decitabine (hazard ratio [HR], 1.11; 95% confidence interval [CI], 1.01-1.21; P = .02). The findings were similar when evaluating only patients completing ≥4 cycles (42% of patients treated with either azacitidine or decitabine). These findings lost significance when evaluating those completing a standard 7-day schedule of azacitidine (34%) vs 5-day schedule for decitabine (66%) (HR, 0.95; 95% CI, 0.83-1.08; P = .43). Red blood cell (RBC) transfusion independence (TI) was achieved in one-third of patients with no difference between the 2 HMAs. In conclusion, the majority of older AML patients did not receive the minimum of 4 cycles of HMA often needed to elicit clinical benefit. We observed no clinically meaningful differences between azacitidine- and decitabine-treated patients in their achievement of RBC TI or survival.

12 July 2018 in European Journal of Haematology
Verified
Journal Article
Closed access
PDF file
RSRory Shallis
Rory Shallis
RARami Ahmad
Rami Ahmad
Amer M. ZeidanAmer M. Zeidan
Amer M. Zeidan


20 April 2020 in Blood Advances
Verified
Journal Article
Open access
PDF file
Amer M. ZeidanAmer M. Zeidan
Amer M. Zeidan
NPNikolai A. Podoltsev
Nikolai A. Podoltsev
XWXiaoyi Wang
Xiaoyi Wang
CZChi Zhang
Chi Zhang
JBJan Bewersdorf
Jan Bewersdorf
RWRong Wang
Rong Wang
Cytarabine-anthracycline based intensive induction chemotherapy (IC) remains the standard of care for remission induction among fit patients with newly diagnosed acute myeloid leukemia (AML) in the United States (US). However, the mortality rate outside of clinical IC trials, predictors of death, and resource utilization during admission for IC have not been thoroughly examined. We used the Premier Healthcare database to identify adult patients (aged 18-89 years) treated with cytarabine-anthracycline-based IC during their first recorded inpatient stay for AML during the contemporary period of 2010 to 2017. We identified factors associated with inpatient death or discharge to hospice, using multivariable logistic regression models. We also assessed the patterns of inpatient healthcare resource utilization. A total of 6442 patients with AML from 313 hospitals who were treated with IC were identified. Median age was 61 years (interquartile range [IQR], 50-68 years), and 56% were men. Median length of stay was 29 (IQR, 25-38) days, with rates of in-hospital death and discharge to hospice of 12.3% and 3.7% (17.9% and 6.3% among patients aged ≥65 years), respectively. Predictors of in-hospital death or discharge to hospice included older age, geographic region, and lower hospital volume. During admission, 28.0%, 12.6%, and 4.0% of patients required treatment in intensive care units, mechanical ventilation, and dialysis, respectively. Despite improvements in supportive care in the contemporary era, inpatient mortality during first hospitalization for adult patients with AML treated with IC in the US remains high particularly among older patients.